A Study to Evaluate Efficacy and Safety of Lenvatinib Combined With Tislelizumab in Patients With FHRCC
Status:
Not yet recruiting
Trial end date:
2025-12-31
Target enrollment:
Participant gender:
Summary
FHRCC is a rare kind of renal cell carcinoma with a morbidity of 1/2000000 per year.Although
several combination therapies demonstrated possible efficacy in this population. No standard
treatment has been approved. The purpose of this study is to evaluate the efficacy and safety
of Lenvatinib in combination with tislelizumab in the first line treatment of patients with
locally advanced/metastatic FHRCC.